Shares of drug firm Wockhardt are in action even as the benchmark indices declined in early trade on Tuesday, December 2, 2025, amid uncertainty over repo rate cuts. The counter opened in green at Rs 1492.95
against the previous close of Rs 1,470.90 on the BSE. It gained further amid a spurt in volume by more than 11.43 times to touch the high of Rs 1,566.95, representing a gain of 6.53 per cent from the previous close. On the National Stock Exchange (NSE), the stock began the session at Rs 1,492 and touched a high of Rs 1,566.90. Last seen, the stock was trading at Rs 1,520.45 and the market cap of the company stood at Rs 24,705.12 crore.
The stock has a 52-week high of Rs 1,870 and a 52-week low of Rs 1,109.60.
The counter has been gaining for the last two days and has risen 24.05 per cent in the period. Earlier on Monday, the stock had it an upper circuit of Rs 1480.25 on the BSE. Technically, the stock trades higher than the 5-day, 20-day, 50-day, 100-day and 200-day moving averages.
Gets NDA status for novel antibiotic Zaynich
The Mumbai-based drugmaker has stated that the US health regulator has accepted the new drug application (NDA) status for its novel, first-in-class antibiotic Zaynich.
The NDA was filed on September 30, 2025, and its acceptance marks a transformative moment - not only for Wockhardt, but also for the entire Indian pharmaceutical industry, the Mumbai-based drug maker said in a statement.
"This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the US FDA," it added.
Submitting an NDA to the US FDA represents one of the most stringent scientific and regulatory thresholds in global drug development, the company said.
Zaynich has been granted fast-track designation by the USFDA, recognising its potential to address urgent and unmet medical needs, it added.
ALSO READ | Aequs IPO GMP vs Meesho IPO GMP vs Vidya Wires IPO GMP: Here's what grey market premium signals
